This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The recent report by Graham et al¹ provides much needed insights into the comparative benefits of 2 gastroprotective therapies: misoprostol and the proton pump inhibitor lansoprazole. Clinicians are now especially eager for evidence-based guidance in the treatment of patients who have a history of endoscopically documented gastric ulceration without Helicobacter pylori infection and who require long-term therapy with a nonsteroidal anti-inflammatory drug (NSAID). However, the use of misoprostol (200 µg 4 times a day [800 µg/d], the maximum recommended dose) does not reflect the current realities of clinical practice.

In Graham and colleagues' 12-week study, misoprostol (200 µg 4 times a day) was clearly superior to lansoprazole (15 or 30 mg/d) for the prevention of gastric ulcers in the analysis of patients who were continuing to receive therapy. The significant treatment differences disappeared, however, in the intention-to-treat analysis, which counted patients who discontinued therapy for any reason as treatment failures. . . . [Full Text of this Article]

RELATED ARTICLE

Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs: Results of a Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Study of Misoprostol vs Lansoprazole
David Y. Graham, Naurang M. Agrawal, Donald R. Campbell, Marian M. Haber, Cyndy Collis, Nancy L. Lukasik, and Bidan Huang
Arch Intern Med. 2002;162(2):169-175.
ABSTRACT | FULL TEXT